Document
IPR2023-00724, No. 1026 Exhibit - Harrisons 2008 (P.T.A.B. Mar. 16, 2023)
Cite Document
IPR2023-00724, No. 1026 Exhibit - Harrisons 2008 (P.T.A.B. Mar. 16, 2023)
+ More Snippets
Document
IPR2023-00724, No. 1058 Exhibit - Blonde 2012 (P.T.A.B. Mar. 16, 2023)
Cite Document
IPR2023-00724, No. 1058 Exhibit - Blonde 2012 (P.T.A.B. Mar. 16, 2023)
+ More Snippets
Document
IPR2023-00724, No. 1098 Exhibit - Exhibit 1098 Garber 2011a (P.T.A.B. May. 22, 2024)
Cite Document
IPR2023-00724, No. 1098 Exhibit - Exhibit 1098 Garber 2011a (P.T.A.B. May. 22, 2024)
+ More Snippets
Document
IPR2023-00724, No. 1104 Exhibit - Exhibit 1104 Vahl (P.T.A.B. May. 22, 2024)
Cite Document
IPR2023-00724, No. 1104 Exhibit - Exhibit 1104 Vahl (P.T.A.B. May. 22, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2007 Exhibit - EX2007 Excerpt of Novo Nordisk’s Initial Responses to Defendants’ Initial Invalidity Contentions Regarding US Patent Nos 8,129,343 8,536,122 8,114,833 8...
Cite Document
IPR2023-00724, No. 2007 Exhibit - EX2007 Excerpt of Novo Nordisk’s Initial Responses to Defendants’ Initial Invalidity Contentions Regarding US Patent Nos 8,129,343 8,536,122 8,114,833 8,920,383 9,7
+ More Snippets
Document
IPR2023-00724, No. 2102 Exhibit - EX2102 Marso, SP, et al, Supplementary Appendix to Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes, N Engl J Med, 3751834 1...
Cite Document
IPR2023-00724, No. 2102 Exhibit - EX2102 Marso, SP, et al, Supplementary Appendix to Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes, N Engl J Med, 3751834 1844 2016 (P.T.A.
+ More Snippets
Document
IPR2023-00724, No. 2059 Exhibit - EX2059 Declaration of Vanessa Costain (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2059 Exhibit - EX2059 Declaration of Vanessa Costain (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2436 Exhibit - EX2436 Tanzeum® Prescribing Information rev Dec 2017 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2436 Exhibit - EX2436 Tanzeum® Prescribing Information rev Dec 2017 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 1011 Exhibit - WO421 (P.T.A.B. Mar. 16, 2023)
Cite Document
IPR2023-00724, No. 1011 Exhibit - WO421 (P.T.A.B. Mar. 16, 2023)
+ More Snippets
Document
IPR2023-00724, No. 1071 Exhibit - US6284727 (P.T.A.B. Mar. 16, 2023)
Cite Document
IPR2023-00724, No. 1071 Exhibit - US6284727 (P.T.A.B. Mar. 16, 2023)
+ More Snippets
Document
IPR2023-00724, No. 2531 Exhibit - EX2531 Invokamet and Invokamet XR Prescribing Information rev July 2023 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2531 Exhibit - EX2531 Invokamet and Invokamet XR Prescribing Information rev July 2023 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2020 Exhibit - EX2020 Transcript of January 5, 2024 Deposition of William J Jusko, PhD (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2020 Exhibit - EX2020 Transcript of January 5, 2024 Deposition of William J Jusko, PhD (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2405 Exhibit - EX2405 US Food Drug Administration, Orange Book Approved Drug Products with Therapeutic Equivalence Evaluations, ANDA 205981 (P.T.A.B. Jan. 17, 2...
Cite Document
IPR2023-00724, No. 2405 Exhibit - EX2405 US Food Drug Administration, Orange Book Approved Drug Products with Therapeutic Equivalence Evaluations, ANDA 205981 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2019 Exhibit - EX2019 Transcript of January 5, 2024 Deposition of William J Jusko, PhD (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2019 Exhibit - EX2019 Transcript of January 5, 2024 Deposition of William J Jusko, PhD (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2112 Exhibit - EX2112 Terry, T, et al, Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes Insights from ACCORD, ADVAN...
Cite Document
IPR2023-00724, No. 2112 Exhibit - EX2112 Terry, T, et al, Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes Insights from ACCORD, ADVANCE, and VADT,
+ More Snippets